On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for
treatment of human immunodeficiency virus (HIV)-1 infection in combination with other …

Abstract HIV‐1 integrase (IN) catalyzes the integration of proviral DNA into the host genome,
an essential step for viral replication. Inhibition of IN catalytic activity provides an attractive …

Protein–protein interactions (PPI) represent attractive targets for drug design. Thus, aiming
at a deeper insight into the HSV-1 envelope glycoprotein D (gD), protein–protein docking …

Currently, there are three distinct mechanistic classes of antiretrovirals: inhibitors of the HIV-
1 reverse transcriptase and protease enzymes and inhibitors of HIV entry, including receptor …

Among a large number of HIV-1 integrase (IN) inhibitors, the 8-hydroxy-[1, 6] naphthyridines
(ie, L-870,810) were one of the promising class of antiretroviral drugs developed by Merck …

A one‐pot strategy for constructing trisubstituted pyridine derivatives had been established
via phosphine‐catalyzed annulation and DDQ oxidative aromatization reactions. This …

Highlights•Overview of structural and functional properties of HIV-1 integrase
(IN).•Classifying the HIV-1 integrase strand transfer inhibitors (INSTIs) into ten …

The retroviral protein Integrase (IN) catalyzes concerted integration of viral DNA into host
chromatin to establish a permanent infection in the target cell. We learned a great deal about …

Human cytomegalovirus (HCMV) infects individuals of all ages and establishes a lifelong
latency. Current antiviral drugs are suboptimal in efficacy and safety and ineffective against …

A microwave-assisted, copper-catalyzed, one-pot, two-step reaction is established to access
functionalized [1, 6] naphthyridines in high yields (up to 96%) starting from 2-(N …